Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its Buy rating on the stock.

This increase in valuation came after Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement under which it will acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Enliven Therapeutics, Inc.’s (NASDAQ:ELVN) competitor, through a subsidiary for approximately $6.7 billion.

Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Earlier, on March 24, Mizuho also lifted its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $41 to $45 and maintained its Outperform rating on the stock.

The research firm pointed to recent Phase 1b data for ELVN-001 as the key factor for this increase in the price target. Mizuho sees Enliven Therapeutics, Inc. (NASDAQ:ELVN) as an under-rated asset in the chronic myeloid leukemia market. The firm added that it expects more data from ELVN-001’s Phase 1a/b trial in mid-year.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for cancer treatment.

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.